Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
accepted:
23
04
2021
pubmed:
11
5
2021
medline:
19
1
2022
entrez:
10
5
2021
Statut:
ppublish
Résumé
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) are an essential therapeutic option in the management of various solid tumors, particularly renal cell carcinoma (RCC). However, post-marketing data regarding their potential cardiovascular toxicities are scant. To identify and characterize cardiovascular adverse events (CVAEs) of VEGFR-TKIs indicated for RCC. Disproportionality analysis of the US Food and Drug Administration adverse event reporting system (July 2014-December 2019) using the reporting odds ratio (ROR) and the lower bound of the Information component (IC) 95% credibility interval (IC We identified 51,836 adverse event reports of sunitinib, pazopanib, axitinib, cabozantinib, and lenvatinib in the full database [36% women; median age 65 years (range 57-73)]. CVAEs accounted for 11,784 (23%) of the reports, with hypertension [n = 5548 (11%), ROR = 6.55 (95% CI 6.37-6.74), IC In post-marketing surveillance data, VEGFR-TKIs are associated with increased reporting of various CVAEs, including pericardial diseases, particularly non-malignant pericardial effusion, and aortic dissections. Moreover, VEGFR-TKIs differ in their CVAE reporting patterns. Clinicians should be conscious of these findings in the care of VEGFR-TKIs recipients.
Sections du résumé
BACKGROUND
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) are an essential therapeutic option in the management of various solid tumors, particularly renal cell carcinoma (RCC). However, post-marketing data regarding their potential cardiovascular toxicities are scant.
OBJECTIVE
To identify and characterize cardiovascular adverse events (CVAEs) of VEGFR-TKIs indicated for RCC.
PATIENTS AND METHODS
Disproportionality analysis of the US Food and Drug Administration adverse event reporting system (July 2014-December 2019) using the reporting odds ratio (ROR) and the lower bound of the Information component (IC) 95% credibility interval (IC
RESULTS
We identified 51,836 adverse event reports of sunitinib, pazopanib, axitinib, cabozantinib, and lenvatinib in the full database [36% women; median age 65 years (range 57-73)]. CVAEs accounted for 11,784 (23%) of the reports, with hypertension [n = 5548 (11%), ROR = 6.55 (95% CI 6.37-6.74), IC
CONCLUSIONS
In post-marketing surveillance data, VEGFR-TKIs are associated with increased reporting of various CVAEs, including pericardial diseases, particularly non-malignant pericardial effusion, and aortic dissections. Moreover, VEGFR-TKIs differ in their CVAE reporting patterns. Clinicians should be conscious of these findings in the care of VEGFR-TKIs recipients.
Identifiants
pubmed: 33970401
doi: 10.1007/s11523-021-00817-2
pii: 10.1007/s11523-021-00817-2
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
471-483Références
Levitzki A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol. 2013;53:161–85.
pubmed: 23043437
Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283–316.
pubmed: 10508235
Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385–403.
pubmed: 26775688
Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375:1457–67.
pubmed: 27732808
Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol. 2015;66:1160–78.
pubmed: 26337996
Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474–502.
pubmed: 32231332
Totzeck M, Mincu RI, Mrotzek S, Schadendorf D, Rassaf T. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol. 2018;25:482–94.
pubmed: 29376753
Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF). J Cell Mol Med. 2005;9:777–94.
pubmed: 16364190
pmcid: 6740098
Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9.
pubmed: 22056247
Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Hear Fail. 2013;1:72–8.
Sonpavde G, Je Y, Schutz F, Galsky MD, Paluri R, Rosenberg JE, et al. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2013;87:80–9.
pubmed: 23317774
Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance. Target Oncol. 2020;15:449–66.
pubmed: 32725437
pmcid: 7434791
Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74:1667–78.
pubmed: 31558250
Huang J, Meng L, Yang B, Sun S, Luo Z, Chen H. Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: a disproportionality analysis of FDA adverse event reporting system. Sci Rep. 2020;10(1):4803.
pubmed: 32179761
pmcid: 7075865
Powles T, Albiges L, Staehler M, Bensalah K, Dabestani S, Giles RH, et al. Updated European Association of Urology Guidelines: recommendations for the treatment of first-line metastatic clear cell renal cancer. Eur Urol. 2018;73:311–5.
pubmed: 29223605
Angulo JC, Shapiro O. The changing therapeutic landscape of metastatic renal cancer. Cancers. 2019;11:1–13.
Raschi E, Poluzzi E, Salvo F, Pariente A, De Ponti F, Marchesini G, et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 2018;28:533–42.
pubmed: 29625780
Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427–36.
pubmed: 19358225
Harpaz R, Dumouchel W, Lependu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93:539–46.
pubmed: 23571771
Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57–69.
pubmed: 21705438
Harpaz R, Odgers D, Gaskin G, Dumouchel W, Winnenburg R, Bodenreider O, et al. A time-indexed reference standard of adverse drug reactions. Sci Data. 2014;1:140043.
pubmed: 25632348
pmcid: 4306188
Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579–89.
pubmed: 30442497
pmcid: 6287923
Herrmann J. Vascular toxic effects of cancer therapies. Nat Rev Cardiol. 2020;17(8):503–22.
pubmed: 32218531
Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis. Cancer Treat Rev. 2017;53:120–7.
pubmed: 28104567
Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011–9.
pubmed: 18083403
pmcid: 2643085
Hatem R, Bebawi E, Schampaert E. Potential sunitinib-induced coronary artery and aortic dissections. Can J Cardiol. 2017;33:830.e17-830.e18.
Edeline J, Laguerre B, Rolland Y, Patard JJ. Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma. Ann Oncol. 2009;21:186–7.
pubmed: 19875754
Niwa N, Nishiyama T, Ozu C, Yagi Y, Saito S. Acute aortic dissection in a patient with metastatic renal cell carcinoma treated with axitinib. Acta Oncol. 2015;54:567–8.
Oshima Y, Tanimoto T, Yuji K, Tojo A. Association between aortic dissection and systemic exposure of vascular endothelial growth factor pathway inhibitors in the Japanese Adverse Drug Event Report database. Circulation. 2017;135:815–7.
pubmed: 28223329
Kust D, Kruljac I, Peternac AŠ, Ostojić J, Prpić M, Čaržavec D, et al. Pleural and pericardial effusions combined with ascites in a patient with severe sunitinib-induced hypothyroidism. Acta Clin Belg. 2016;71(3):175–7.
pubmed: 26319226
Krauth MT, Herndlhofer S, Schmook MT, Mitterbauer-Hohendanner G, Schlögl E, Valent P. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica. 2011;96:163–6.
pubmed: 20934998
Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol. 2009;4:99–105.
pubmed: 19381453
Quintás-Cardama A, Kantarjian H, O’Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908–14.
pubmed: 17761974
Fogli S, Porta C, Del Re M, Crucitta S, Gianfilippo G, Danesi R, et al. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treat Rev. 2020;84:101966.
pubmed: 32044644
Aragon-Ching JB, Ning YM, Dahut WL. Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab. Acta Oncol. 2008;47:1600–1.
pubmed: 18607842
pmcid: 7217319
Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier oncology group GU 04–75. J Clin Oncol. 2011;29:1525–30.
pubmed: 21422406
Pucci G, Milan A, Paini A, Salvetti M, Cerasari A, Vaudo G. Acute blood pressure elevation associated with biological therapies for cancer: a focus on VEGF signaling pathway inhibitors. Expert Opin Biol Ther. 2019;19:433–42.
pubmed: 30888868
Shamloo BK, Chhabra P, Freedman AN, Potosky A, Malin J, Smith SW. Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis. Drug Saf. 2012;35:507–18.
pubmed: 22612854
Bonnet C, Sibon I. Potential role of anti-VEGF targeted therapies in cervical artery dissection: a case report. Rev Neurol. 2015;171:677–9.
pubmed: 25912472
Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, et al. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2012;118:1868–76.
pubmed: 21898375
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;7:621–51.
Mahé J, de Campaigno EP, Chené A-L, Montastruc J-L, Despas F, Jolliet P. Pleural adverse drugs reactions and protein kinase inhibitors: identification of suspicious targets by disproportionality analysis from VigiBase. Br J Clin Pharmacol. 2018;84:2373–83.
pubmed: 29943846
pmcid: 6138511
Patras de Campaigno E, Bondon-Guitton E, Laurent G, Montastruc F, Montastruc J-L, Lapeyre-Mestre M, et al. Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics. Br J Clin Pharmacol. 2017;83:1544–55.
pubmed: 28098949
pmcid: 5465347
Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385–96.
pubmed: 16689555
Bégaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. J Am Med Assoc. 2002;288:1588.